Daniele Balducci
Overview
Explore the profile of Daniele Balducci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Capobianco I, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685651
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are...
2.
Balducci D, Ratone J, Schaefer M, Godat S, Perez-Cuadrado-Robles E, Hoibian S, et al.
Gastrointest Endosc
. 2024 Jul;
101(1):117-122.
PMID: 39038522
Background And Aims: EUS-guided hepaticogastrostomy (EUS-HGS) is an effective biliary drainage technique for patients with altered anatomy or duodenal strictures. EUS-guided hepaticojejunostomy (EUS-HJS) can be used to create a fistula...
3.
Argenziano M, Kim M, Montori M, Di Bucchianico A, Balducci D, Ahn S, et al.
Hepatol Int
. 2024 Jul;
18(Suppl 2):922-940.
PMID: 39012579
Hepatocellular carcinoma (HCC) is undergoing a transformative shift, with metabolic-associated fatty liver disease (MAFLD) emerging as a dominant etiology. Diagnostic criteria for MAFLD involve hepatic steatosis and metabolic dysregulation. Globally,...
4.
Balducci D, Montori M, Martini F, Valvano M, De Blasio F, Argenziano M, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611050
Endoluminal biliary radiofrequency ablation (RFA) has been proposed as a palliative treatment for patients with malignant biliary obstruction (MBO) in order to improve stent patency and survival. However, the existing...
5.
Balducci D, Archimbaud C, Ratone J, Dahel Y, Hoibian S, Caillol F, et al.
Endoscopy
. 2024 Apr;
56(S 01):E325.
PMID: 38594002
No abstract available.
6.
Martini F, Balducci D, Mancinelli M, Buzzanca V, Fracchia E, Tarantino G, et al.
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685780
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease with a heterogeneous presentation, symptomatology, disease progression, and response to therapy. The current risk stratification assessment, aimed at identifying patients...
7.
Balducci D, Montori M, De Blasio F, Di Bucchianico A, Argenziano M, Svegliati Baroni G, et al.
Medicina (Kaunas)
. 2023 Jun;
59(6).
PMID: 37374354
Liver cancer is very frequent, and hepatocellular carcinoma (HCC) accounts for the majority of liver cancer cases. Its growing incidence has been greatly affected by the increasing prevalence of metabolic-associated...
8.
Montori M, Scorzoni C, Argenziano M, Balducci D, De Blasio F, Martini F, et al.
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362726
Cholangiocarcinoma (CCA) is an aggressive neoplasia with an increasing incidence and mortality. It is characterized by a strong desmoplastic stroma surrounding cancer cells. Cancer-associated fibroblasts (CAFs) are the main cell...
9.
Balducci D, Quatraccioni C, Benedetti A, Marzioni M, Maroni L
Explor Target Antitumor Ther
. 2022 Sep;
2(2):174-186.
PMID: 36046145
Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer...
10.
Bertuccioli A, Cardinali M, DI Pierro F, Balducci D
Med Hypotheses
. 2021 Apr;
150:110587.
PMID: 33831722
No abstract available.